Tag: Oncology

Boston Biomedical Entered into Alliance with World-Leading Oncology Centers

r&d
Boston Biomedical, Inc. announced that the company has entered into an alliance in oncology research with three world-leading oncology centers of excellence – Columbia University, Harvard University a...

Gotham Therapeutics & ProQinase Confirm Oncology Profiling Cascade

Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and ProQinase, an early stage drug-discovery company, recently acquired by Malvern/PA-based...

Thermo Fisher in Agreement with Lilly

Thermo Fisher Scientific announced an agreement with Eli Lilly and Company for development of a companion diagnostic that will use the U.S Food and Drug Administration-approved, next-generation sequen...

Imfinzi Showed Improved OS in SCLC Treating

AstraZeneca’s Imfinzi (durvalumab) has become the first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer (SCLC), after ...

Novartis and BenevolentAI to Search New Uses for Oncology Drugs

novartis
The Artificial Intelligence (AI)-based drug development firm BenevolentAI has signed an agreement with Novartis to find potential new uses for oncology drugs already in its pipeline. UK-based Benev...

Harbour BioMed Announced Strategic Collaboration to Develop HBM’s Innovative Therapeutics

lab research
Harbour BioMed, a global clinical-stage biopharmaceutical company, and Pharmaceutical Product Development, a leading global contract research organization, announced a strategic collaboration to devel...

Australian Scientists Found Potential Compound for Cancer Treatment

The remarkable ability of a small Australian sea snail to produce a colorful purple compound to protect its eggs is proving even more remarkable for its potential in a new anti-cancer pharmaceutical. ...

Global Cervical Cancer Vaccine Market to Increase

A new piece of research estimates that the global cervical cancer vaccine market will increase at a compound annual growth rate (CAGR) of 12.1 percent during the forecast period 2019 to 2026. Estim...

AmerisourceBergen and OneOncology in Long-Term Strategic Relationship

AmerisourceBergen, a global healthcare solutions leader, announced that it has entered a long-term strategic relationship with OneOncology, the national partnership of community oncologists driving th...

Immuno-Oncology Imaging Company in Collaboration with Roche

roche
ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced today that it has entered into a non-exclusive license and collaboration agreement with Roche. Under the terms of the agreeme...

Sandoz Announced Launch of Generic Oncology Medicine Gefitinib in 13 EU Countries

Sandoz
Sandoz announced the launch of the generic oncology medicine gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK,...

EMA to Review MAA for First China-Developed Trastuzumab Biosimilar

First trastuzumab developed in China following the National Medical Products Administration (NMPA) technical guideline for biosimilar with the New Drug Application (NDA) received the acceptance for re...

Pfizer Received FDA Approval for Avastin® Biosimilar

Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ZIRABEV™ (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab), for the treatment of five type...

PhoenixMD and WuXi STA Produced Multikilogram Drug Supply for TNBC Treatment

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices. Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designi...

Biocartis and Kite in Master Development and Commercialization Agreement

Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that it has entered into a Master Development and Commercialization Agreement with Kite, a G...

ProBioGen and Abcuro in GMP Manufacturing Agreement

ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, announced the closing of a services and license agreement with Abcuro, Inc. Pursuing a new...